<DOC>
	<DOCNO>NCT01218633</DOCNO>
	<brief_summary>Multiple study examine effect endogenous GLP-1 secretion use competitive antagonist GLP-1 - Exendin-9,39 - infuse rate 300pmol/kg/min . However , presence effect necessarily imply effect due blockade endogenous GLP-1 action receptor . It possible supraphysiologic concentration Exendin may effect . To examine effect Exendin glucose metabolism investigator propose dose-response study determine whether compound effect dose-dependent fashion .</brief_summary>
	<brief_title>Dose-response Study Exendin-9,39 Glucose Metabolism</brief_title>
	<detailed_description />
	<criteria>Healthy Not medication thyroid hormone replacement OCP No history diabetes No prior upper GI surgery</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>